Ozone Pharmaceuticals has introduced a uniform pricing strategy for its products in the therapeutic segments of cholesterol, diabetes and hypertension.
Announcing this at a press conference here today, company chairman S C Sehgal said any product from the company for treatment of diabetes, cholesterol and hyper tension will be same. Each tablet will cost only Rs.2 under uniform pricing strategy.
The products now will be available at Rs.2 per tablet will be (Ozovas 10 and Ozovas 20) atorvastatin 10/20mg, (Ozovas F) atorvastatin 10mg + fenofibrate 160mg) meant for lipid management, (Ozotel) telmisartan 40mg, (Ozotel H) telmisartan 40mg + HCTZ 12.5mg) for hyper tension, and (Ozopride 1 and Ozopride 2) glimepiride 1/2mg, (Ozomet) metformin ER 500mg, and (Ozomet G1 and Ozomet G2) metformin ER 500 mg+ glimepride 1/2mg+pioglitazone zone 15mg for diabetes.
“Today household expenditure on drugs constitutes more than 50 per cent of all out-of-pocket spending on health. Reducing this burden requires a carefully crafted plan, Uniform Pricing Strategy (UPS) is a first ever initiative by Ozone Pharmaceuticals assuring affordable access to drugs that can make a big difference,” he claimed.
“India is very soon going to be world’s capital for chronic diseases such as hypertension, high blood pressure, high cholesterol and diabetes. Medicines to manage these diseases are to be taken for life to secure lifelong happiness. In such instances, the highly expensive costing of potent medicines can prevent their optimal dose as per the doctor’s prescription. Through its uniform pricing policy, Ozone Pharmaceuticals perseveres to ascertain an affordable lifelong compliance to medicines,” said A K Sahoo, CEO, Ozone Pharmaceuticals.